Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Good Girl Rx vs GoodRx

Good Girl Rx
Graded #277

Lower grade

vs+7.499999999999993
GoodRx
Graded #116

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 62.1/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +52
28
80
Dose & formulationGood Girl Rx +18
88
70
Clinical oversightGood Girl Rx +12
81
69
Labs & monitoringGood Girl Rx +1
52
51
FulfillmentGood Girl Rx +4
85
81
Contract termsGoodRx +14
41
55
Good Girl Rx · left barGoodRx · right bar

The numbers

MetricGood Girl RxGoodRx
WeighScore62.1/10069.6/100
GradeCC
Scorecard rank#277#116
Semaglutide$79/mo (microdose tier, 12-month plan, compounded)Not disclosed
Tirzepatide$139/mo (microdose tier, 12-month plan, compounded)$299/mo (brand Zepbound)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
Good Girl Rx

Graded #277 · C

Strengths

  • LegitScript certified
  • Multiple formats — injectable, microdose, and ODT pills — for both semaglutide and tirzepatide
  • Dispensed by licensed 503A or 503B pharmacies
  • Limited brand-name options available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • Named legal entity with a Nashville address

Where it loses points

  • The advertised rates require twelve months paid up front; billed month to month the same products are $184 and $244, roughly 2.3 times as much
  • Every plan is prepaid — the discount exists only on the 3-, 6- and 12-month terms
  • The priced products are microdoses, not labelled therapeutic doses; the standard compounded semaglutide is $134/mo and also needs a year up front
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard